Human osteopontin: Potential clinical applications in cancer (Review)
- Authors:
- Chengcheng Hao
- Yuxin Cui
- Sionen Owen
- Wenbin Li
- Shan Cheng
- Wen G. Jiang
-
Affiliations: Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, P.R. China, Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK, Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China - Published online on: April 21, 2017 https://doi.org/10.3892/ijmm.2017.2964
- Pages: 1327-1337
-
Copyright : © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
|
Giachelli CM, Liaw L, Murry CE, Schwartz SM and Almeida M: Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci. 760:109–126. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Weber GF and Cantor H: The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev. 7:241–248. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Denhardt DT and Noda M: Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 30–31(S30–31): 92–102. 1998. View Article : Google Scholar | |
|
Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral Biol Med. 11:279–303. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT and Sørensen ES: Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 282:19463–19472. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Christensen B, Nielsen MS, Haselmann KF, Petersen TE and Sørensen ES: Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 390:285–292. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Christensen B, Petersen TE and Sørensen ES: Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J. 411:53–61. 2008. View Article : Google Scholar | |
|
Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J. 7:1475–1482. 1993.PubMed/NCBI | |
|
Cho HJ, Cho HJ and Kim HS: Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 11:206–213. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer. 90:1877–1881. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and Rudland PS: The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 17:463–474. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 8:212–226. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R and Giachelli CM: Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 271:28485–28491. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and Sheppard D: The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem. 274:36328–36334. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Scatena M, Liaw L and Giachelli CM: Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 27:2302–2309. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sun BS, Li Y, Zhang ZF, You J and Wang CL: Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 96:1943–1951. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao YL, Xing LQ, Ren TJ, Hou JF, Xue Q, Liu C and Han YM: The expression of osteopontin in breast cancer tissue and its relationship with 21ras and CD44V6 expression. Eur J Gynaecol Oncol. 37:41–47. 2016. | |
|
Yang L, Shang X, Zhao X, Lin Y and Liu J: Correlation study between OPN, CD44v6, MMP-9 and distant metastasis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 26:989–992. 2012.In Chinese. | |
|
Kim JS, Bashir MM and Werth VP: Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol. 132:1825–1832. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 169:233–246. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT and Denko NC: The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One. 5:e96332010. View Article : Google Scholar : PubMed/NCBI | |
|
Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, et al: Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 57:302–310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CM, Chen PC, Li TM, Fong YC and Tang CH: Si-Wu-tang extract stimulates bone formation through I3K/Akt/NF-κB signaling pathways in osteoblasts. BMC Complement Altern Med. 13:2772013. View Article : Google Scholar | |
|
Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, et al: Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/I3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol. 90:642–648. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, Nakamura T, Takahashi T, Matsubara H and Oh H: Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway. Biochem Biophys Res Commun. 359:341–347. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen RX, Xia YH, Xue TC, Zhang H and Ye SL: Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep. 25:803–808. 2011. | |
|
Mi Z, Guo H, Wai PY, Gao C and Kuo PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis. 27:1134–1145. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tuck AB, Hota C and Chambers AF: Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat. 70:197–204. 2001. View Article : Google Scholar | |
|
Kerenidi T, Kazakou AP, Lada M, Tsilioni I, Daniil Z and Gourgoulianis KI: Clinical significance of circulating osteopontin levels in patients with lung cancer and correlation with VEGF and MMP-9. Cancer Invest. 34:385–392. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Babarović E, Valković T, Budisavljević I, Balen I, Štifter S, Duletić-Načinović A, Lučin K and Jonjić N: The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma. Pathol Res Pract. 212:509–516. 2016. View Article : Google Scholar | |
|
Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B and Gu X: Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol. 39:539–544. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A and Syrigos KN: The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res. 29:1651–1657. 2009.PubMed/NCBI | |
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and Fu WM: Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW and Brackstone M: Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res. 7:723–732. 2015.PubMed/NCBI | |
|
Friedmann-Morvinski D, Bhargava V, Gupta S, Verma IM and Subramaniam S: Identification of therapeutic targets for glioblastoma by network analysis. Oncogene. 35:608–620. 2016. View Article : Google Scholar | |
|
Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, et al: Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 108:535–540. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Etiz D, Ataizi FC, Bayman E, Akcay M, Acikalin MF, Colak E and Ciftci E: Prognostic value of osteopontin in patients treated with primary radiotherapy for head and neck cancer. Asian Pac J Cancer Prev. 14:5175–5178. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, et al: Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg. 13:1577–1582. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Higashiyama M, Ito T, Tanaka E and Shimada Y: Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 14:3419–3427. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ng L, Wan TM, Lam CS, Chow AK, Wong SK, Man JH, Li HS, Cheng NS, Pak RC, Cheung AH, et al: Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One. 10:e01262192015. View Article : Google Scholar : PubMed/NCBI | |
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI | |
|
Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM and Mulvihill SJ: Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 42:193–197. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ and Goggins M: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 13:487–491. 2004.PubMed/NCBI | |
|
Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gimba ER and Tilli TM: Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 331:11–17. 2013. View Article : Google Scholar | |
|
Salem M, Atti SA, Raziky ME, Darweesh SK and Sharkawy ME: Clinical significance of plasma osteopontin level as a biomarker of hepatocellular carcinoma. Gastroenterology Res. 6:191–199. 2013.PubMed/NCBI | |
|
Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu WL and Ma YC: Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells. Mol Med Rep. 11:3701–3707. 2015.PubMed/NCBI | |
|
Moszynski R, Szubert S, Szpurek D, Michalak S and Sajdak S: Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res. 39:1518–1525. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M and Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res. 32:309–314. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Subramani VN, Narasimhan M, Thiyagarajan M, Munuswamy BD and Jayamani L: Expression of osteopontin in oral squamous cell carcinoma and its surgical margins-an immunohistochemical study. J Clin Diagn Res. 9:ZC66–ZC69. 2015.PubMed/NCBI | |
|
Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, Adany R and Balazs M: The role of osteopontin expression in melanoma progression. Tumour Biol. 36:7841–7847. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, Blomqvist C, Fjällskog ML and Weber GF: Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer. 112:729–738. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E and Peiró G: Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol. 45:504–512. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Feng A, Chen S, Zhang Y, Xie Q, Yang M, Shao Q, Liu J, Yang Q, Kong B, et al: Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1. Cell Mol Immunol. 10:176–182. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, et al: Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Patani N, Jouhra F, Jiang W and Mokbel K: Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 28:4105–4110. 2008. | |
|
Sun SJ, Wu CC, Sheu GT, Chang HY, Chen MY, Lin YY, Chuang CY, Hsu SL and Chang JT: Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth. Oncotarget. 7:55572–55584. 2016.PubMed/NCBI | |
|
Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y and Li W: Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol. 137:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Blasberg JD, Goparaju CM, Pass HI and Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg. 139:1587–1593. 2010. View Article : Google Scholar : | |
|
Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE4, Nasciutti LE and Gimba ER: Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol. 37:2655–2663. 2016. View Article : Google Scholar | |
|
Tilli TM, Bellahcène A, Castronovo V and Gimba ER: Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer. 14:4332014. View Article : Google Scholar : PubMed/NCBI | |
|
Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V and Gimba ER: Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate. 72:1688–1699. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 6:22239–22257. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang MX, Xu YJ, Zhu MC and Yan F: Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 14:7315–7319. 2013. View Article : Google Scholar | |
|
Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 35:1409–1416. 2009.PubMed/NCBI | |
|
Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 26:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B and Zhu Z: Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci. 9:55–66. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Siddiqui AA, Jones E, Andrade D, Shah A, Kowalski TE, Loren DE, Chipitsyna G and Arafat HA: Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol. 29:1321–1327. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sarosiek K, Jones E, Chipitsyna G, Al-Zoubi M, Kang C, Saxena S, Gandhi AV, Sendiky J, Yeo CJ and Arafat HA: Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN. J Gastrointest Surg. 19:639–650. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simões M, Gimba E and Soares P: Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. Eur J Endocrinol. 174:551–561. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, et al: Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget. 7:52003–52016. 2016.PubMed/NCBI | |
|
Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, et al: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro-oncol. 12:765–775. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D and Bache M: Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer. 12:1312012. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue M and Shinohara ML: Intracellular osteopontin (iOPN) and immunity. Immunol Res. 49:160–172. 2011. View Article : Google Scholar | |
|
Shinohara ML, Kim HJ, Kim JH, Garcia VA and Cantor H: Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci USA. 105:7235–7239. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA and Tun HW: Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget. 7:32156–32171. 2016.PubMed/NCBI | |
|
Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C and Sodek J: Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol. 170:88–100. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao W, Wang L, Zhang L, Yuan C, Kuo PC and Gao C: Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists. J Biol Chem. 285:20452–20461. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Junaid A, Moon MC, Harding GE and Zahradka P: Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 292:C919–C926. 2007. View Article : Google Scholar | |
|
Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA and Sodek J: Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol. 184:118–130. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH and Cantor H: Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol. 7:498–506. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP and Brentnall TA: Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas. 39:981–988. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 7:4060–4066. 2001.PubMed/NCBI | |
|
Collins AL, Rock J, Malhotra L, Frankel WL and Bloomston M: Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 19:2673–2678. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ and Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 287:860–864. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chan SC, Tekari A, Benneker LM, Heini PF and Gantenbein B: Osteogenic differentiation of bone marrow stromal cells is hindered by the presence of intervertebral disc cells. Arthritis Res Ther. 18:292015. View Article : Google Scholar | |
|
Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and Kundu GC: Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One. 8:e691162013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH and Yang PC: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 23:953–964. 2005. View Article : Google Scholar | |
|
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wai PY, Guo L, Gao C, Mi Z, Guo H and Kuo PC: Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery. 140:132–140. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sato K, Iwai A, Nakayama Y, Morimoto J, Takada A, Maruyama M, Kida H, Uede T and Miyazaki T: Osteopontin is critical to determine symptom severity of influenza through the regulation of NK cell population. Biochem Biophys Res Commun. 417:274–279. 2012. View Article : Google Scholar | |
|
Collighan RJ and Griffin M: Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids. 36:659–670. 2009. View Article : Google Scholar | |
|
He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 25:2192–2202. 2006. View Article : Google Scholar | |
|
Shen H and Weber GF: The osteopontin-c splice junction is important for anchorage-independent growth. Mol Carcinog. 53:480–487. 2014. View Article : Google Scholar | |
|
Shi Z, Wang B, Chihanga T, Kennedy MA and Weber GF: Energy metabolism during anchorage-independence. Induction by osteopontin-c. PLoS One. 9:e1056752014. View Article : Google Scholar : PubMed/NCBI | |
|
Sivakumar S and Niranjali Devaraj S: Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - osteopontin-c. J Diabetes Metab Disord. 13:132014. View Article : Google Scholar : PubMed/NCBI | |
|
Mi Z, Oliver T, Guo H, Gao C and Kuo PC: Thrombin-cleaved COOH(−) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 67:4088–4097. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chimparlee N, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Payungporn S, Poovorawan Y and Tangkijvanich P: Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 16:7211–7217. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma A, Hong S, Singh R and Jang J: Single-walled carbon nanotube based transparent immunosensor for detection of a prostate cancer biomarker osteopontin. Anal Chim Acta. 869:68–73. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Faria M, Halquist MS, Yuan M, Mylott W Jr, Jenkins RG and Karnes HT: Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 1001:156–168. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Meirinho SG, Dias LG, Peres AM and Rodrigues LR: Development of an electrochemical RNA-aptasensor to detect human osteopontin. Biosens Bioelectron. 71:332–341. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Mei Q, Jia S, Koh K, Wang K and Liu X: High specific detection of osteopontin using a three-dimensional copolymer layer support based on electrochemical impedance spectroscopy. Analyst (Lond). 139:4476–4481. 2014. View Article : Google Scholar |
